FSFaouzi Saliba

Faouzi Saliba

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Faouzi Saliba has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:

  • Philippe Ichaï

    AP-HP Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France; Univ Paris-Sud, UMR-S 785, Villejuif, France; Inserm, Unité 785, 94800 Villejuif, France

    8 shared publications
  • Didier Samuel

    APHP, Hôpital Paul Brousse, Centre Hépato-Biliaire, Unité Inserm 1193, Université Paris-Saclay, Villejuif

    7 shared publications
  • Didier Samuel

    5 shared publications
  • Daniel Azoulay

    AP‐HP Hopital Paul Brousse Centre Hepato‐Biliaire Villejuif France

    4 shared publications
  • Denis Castaing

    AP‐HP Hopital Paul Brousse Centre Hepato‐Biliaire Villejuif France

    4 shared publications
  • Lutz Fischer

    Department of Hepatobiliary Surgery and Transplantation, University Medical Center Eppendorf, Hamburg, Germany

    4 shared publications

Latest Publications

  • Re: Association Between Renal Dysfunction and Major Adverse Cardiac Events After Liver Transplantation: Evidence From an International Randomized Trial of Everolimus-Based Immunosuppression

    by Faouzi Saliba, Lutz Fischer, Paolo de Simone, Peter Bernhardt, Giovanni Bader, John Fung

    Ann Transplant. 2018 Oct 26;23:751-757. doi: 10.12659/AOT.911030. PMID: 30361470, PMCID: PMC6248043 In the paper, the sentence on page 754, first column, lines 4, 5, and 6 has been incorrectly written: At the month 24 study visit, mean (SD) eGFR was 74.7 (26.1), 67.8 (21.0), and 77.5 (26.2) mL/min/1.73 m2 in the EVR/rTAC, TAC Elimination, and TAC Control groups, respectively (p=0.007). The corrected sentence should read: At the 24-month study visit, mean (SD) eGFR was 74.7 (26.1), 67.8 (21.0), and 77.5 (26.2) mL/min/1.73 m2 in the EVR/rTAC, TAC Control, and TAC Elimination groups, respectively (p=0.007).


  • Association Between Renal Dysfunction and Major Adverse Cardiac Events After Liver Transplantation: Evidence from an International Randomized Trial of Everolimus-Based Immunosuppression

    by Faouzi Saliba, Lutz Fischer, Paolo de Simone, Peter Bernhardt, Giovanni Bader, John Fung

    BACKGROUND Prospective evidence is lacking regarding the association between renal dysfunction and cardiovascular events after liver transplantation. MATERIAL AND METHODS Data were analyzed post hoc regarding renal function and major adverse cardiac events in a two-year prospective trial of de novo liver transplant recipients randomized at 30 days post-transplant to (i) everolimus [EVR]/reduced tacrolimus [EVR/rTAC] (ii) EVR with tacrolimus discontinued [TAC Elimination] or (iii) standard tacrolimus [TAC Control]. RESULTS By month 24 post-transplant, 32/716 patients had experienced a first major cardiac event (4.5%): 4.1% (10/245), 2.2% (5/229) and 7.0% (17/242) of patients in the EVR/rTAC, TAC Elimination and TAC Control groups, respectively (p=0.043). The cumulative eGFR area under the curve (AUC) from randomization to month 24 was 119 706, 123 082, and 105 946 mL in the EVR/rTAC, TAC Elimination, and TAC Control groups, respectively, corresponding to a mean eGFR AUC of 82.4, 83.0, and 71.9 mL/min/1.73 m². Cox regression modeling showed that mean eGFR AUC was inversely associated with time to first major cardiac event: the hazard ratio per mL/min/1.73 m² was -0.0000015 [95% CI -0.00000078; -0.0000024] (p<0.001). CONCLUSIONS These findings confirm retrospective evidence that the risk of major cardiac events increases with deteriorating renal function after liver transplantation and demonstrate the need for careful cardiovascular risk management in patients with renal impairment. Immunosuppression based on everolimus with tacrolimus withdrawal, or to a lesser extent tacrolimus reduction, improves both renal function and the risk of major cardiac events compared to standard tacrolimus therapy in liver transplant recipients.


  • Open Access

    Submucosal hematoma: a new distinctive sign during emergency upper digestive endoscopy for ammonia ingestion

    by Moana Gelu-Simeon, Anh-Phuc Chuong, Faouzi Saliba, Guillaume Thiery, Marc Laurent, Claire Vilain, Marius Borel, Leonardo Amaral, Marceline Alexis, Georgette Saint-Georges, et al.

    Submucosal hematoma has never been associated with caustic injuries. Long-term follow-up of patients who ingested ammonia is not well known and ammonia ingestion is rare. In a Single-center observational study, prospective data were collected from 2009 to 2013, in patients over the age of 14 years old referred for ammonia ingestion. The emergency and follow-up endoscopic data and the outcome were reported. Ammonia ingestion occurred in 43 patients. Submucosal hematoma of the gastric wall was a distinctive endoscopic sign observed in 15 (34.8%) cases. Oropharyngeal lesions were present in 30 (69.8%) patients, which was associated with ingestion with suicidal intent in 18 cases. Mild and severe endoscopic lesions (grade IIB to IIIB) were found in 16 (37.2%) cases with 10 (23.3%) cases presenting submucosal hematoma at initial endoscopy. A complete spontaneous gastric healing was frequently observed in 36 (83.7%) cases. In 11 cases with submucosal hematoma, a favourable outcome was observed with a medical treatment, however 6 of these patients had severe endoscopic lesions initially. Submucosal hematoma of the gastric wall is an endoscopic sign occurring frequently in ammonia ingestion. Submucosal hematoma should be distinguished from necrosis in order to avoid false misclassification in favour of more severe lesions, which would lead to an abusive surgery.


  • Open Access

    Proceedings of Réanimation 2017, the French Intensive Care Society International Congress

    by Chtara Kamilia, Kais Regaieg, Najeh Baccouch, Hedi Chelly, Mabrouk Bahloul, Mounir Bouaziz, Ali Jendoubi, Ahmed Abbes, Houda Belhaouane, Oussama Nasri, et al.


  • Use of everolimus in liver transplantation: The French experience

    by Jérôme Dumortier, Sebastien Dharancy, Yvon Calmus, Christophe Duvoux, François Durand, Ephrem Salamé, Faouzi Saliba


  • Open Access

    Reply to Winston et al

    by Faouzi Saliba, Lutz Fischer

    To the Editor—We thank Winston and colleagues for their comments on our manuscript, “Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients.”

  • Open Access

    Randomized Trial of Micafungin for the Prevention of Invasive Fungal Infection in High-Risk Liver Transplant Recipients

    by Faouzi Saliba, Andreas Pascher, Olivier Cointault, Pierre-François Laterre, Carlos Cervera, Jan J. De Waele, Umberto Cillo, Róbert M. Langer, Manuela Lugano, Stephen Phillips, et al.

    Background. Invasive fungal infection (IFI) following liver transplant is associated with significant morbidity and mortality. Antifungal prophylaxis is rational for liver transplant patients at high IFI risk. Methods. In this open-label, noninferiority study, patients were randomized 1:1 to receive intravenous micafungin 100 mg or center-specific standard care (fluconazole, liposomal amphotericin B, or caspofungin) posttransplant. The primary endpoint was clinical success (absence of a proven/probable IFI and no need for additional antifungals) at end of prophylaxis (EOP). Noninferiority (10% margin) of micafungin vs standard care was assessed in the per protocol and full analysis sets. Safety assessments included adverse events and liver and kidney function tests. Results. The full analysis set comprised 344 patients (172 micafungin; 172 standard care). Mean age was 51.2 years; 48.0% had a Model for End-Stage Liver Disease score ≥20. At EOP (mean treatment duration, 17 days), clinical success was 98.6% for micafungin and 99.3% for standard care (Δ standard care – micafungin [95% confidence interval], 0.7% [−2.7% to 4.4%]) in the per protocol set and 96.5% and 93.6%, respectively (−2.9% [−8.0% to 1.9%]), in the full analysis set. Incidences of drug-related adverse events for micafungin and standard care were 11.6% and 16.3%, leading to discontinuation in 6.4% and 11.6% of cases, respectively. At EOP, liver function tests were similar but creatinine clearance was higher in micafungin- vs standard care–treated patients. Conclusions. Micafungin was noninferior to standard care as antifungal prophylaxis in liver transplant patients at high risk for IFI. Adverse event profiles and liver function at EOP were similar, although kidney function was better with micafungin. Clinical Trials Registration. NCT01058174.


  • Open Access

    Hyponatremia influences the outcome of patients with acute-on-chronic liver failure: an analysis of the CANONIC study

    by Andrés Cárdenas, Elsa Solà, Ezequiel Rodríguez, Rogelio Barreto, Isabel Graupera, Marco Pavesi, Faouzi Saliba, Tania Mara Welzel, Javier Martinez-Gonzalez, Thierry Gustot, et al.

    Hyponatremia is a marker of poor prognosis in patients with cirrhosis. This analysis aimed to assess if hyponatremia also has prognostic value in patients with acute-on-chronic liver failure (ACLF), a syndrome characterized by acute decompensation of cirrhosis, organ failure(s) and high short-term mortality. We performed an analysis of the Chronic Liver Failure Consortium CANONIC database in 1,341 consecutive patients admitted to 29 European centers with acute decompensation of cirrhosis (including ascites, gastrointestinal bleeding, hepatic encephalopathy, or bacterial infections, or any combination of these), both with and without associated ACLF (301 and 1,040 respectively). Of the 301 patients with ACLF, 24.3% had hyponatremia at inclusion compared to 12.3% of 1,040 patients without ACLF (P <0.001). Model for end-stage liver disease, Child-Pugh and chronic liver failure-SOFA scores were significantly higher in patients with ACLF and hyponatremia compared to those without hyponatremia. The presence of hyponatremia (at inclusion or during hospitalization) was a predictive factor of survival both in patients with and without ACLF. The presence of hyponatremia and ACLF was found to have an independent effect on 90-day survival after adjusting for the potential confounders. Hyponatremia in non-ACLF patients nearly doubled the risk (hazard ratio (HR) 1.81 (1.33 to 2.47)) of dying at 90 days. However, when considering patients with both factors (ACLF and hyponatremia) the relative risk of dying at 90 days was significantly higher (HR 6.85 (3.85 to 12.19) than for patients without both factors. Patients with hyponatremia and ACLF had a three-month transplant-free survival of only 35.8% compared to 58.7% in those with ACLF without hyponatremia (P <0.001). The presence of hyponatremia is an independent predictive factor of survival in patients with ACLF. In cirrhosis, outcome of patients with ACLF is dependent on its association with hyponatremia.


    • 4 November 2014
      • Vol. 106  (1) , 35-43

    Artificial liver support: a real step forward.

    by F Saliba, D Samuel

    Since the early 1960s, several authors reported on the use of some experimental artificial liver devices in order to support patients with either acute liver failure (ALF) or end-stage chronic liver disease. In the 1980s, liver transplantation became an established real treatment replacing the whole liver with a major survival benefit. In the 1990s, the concept of albumin dialysis appeared as a new revolution in the concept of dialysis with the great capacity of removal of toxins, drugs and molecules strongly bound to albumin. Currently, three artificial liver support devices are available: The MARS®, the Prometheus® and the SPAD®. The most widely studied and used system is the MARS® that uses albumin dialysis to replace the detoxification function of the liver. MARS has shown in several uncontrolled studies and few randomized studies an improvement in the patient condition in terms of clinical symptoms (hepatic encephalopathy, pruritus, jaundice) and in liver and kidney biological parameters bringing these patients safely to liver transplantation. MARS® has shown for some patients with ALF (mainly paracetamol intoxication) an improvement of spontaneous or transplant free survival. The use of MARS in acute on chronic liver failure (ACLF) require further studies based on strict definition of the syndrome. The use of albumin dialysis technique, require the performance of multiple sessions of treatment or even (in situations of ALF) a continuous treatment in order to improve spontaneous recovery or bridge these patients to liver transplantation. The performance of these systems would need further improvement. Large randomized trials are still needed in both patients with ALF and ACLF to establish the indications, the timing and the real place of liver support therapies. Meanwhile, early use of these devices in patients with ALF and ACLF could be considered as an additional tool among others in the management of these patients in specialized liver units.